Swiss drugmaker Novartis (NOVN.S) said on Tuesday it has reached a definitive agreement to buy Fort Worth, Texas-based Encore Vision, which is focused on developing a novel treatment in presbyopia, or far-sightedness.

"There is a large need for innovative, effective and safe treatment options for people with presbyopia, and there is currently no disease-modifying treatment available at all," Vasant Narasimhan, Novartis' global head, drug development and chief medical officer said in a statement.

Financial details of the transaction are not disclosed, Basel-based Novartis said.

About Video

GMT TIME

14:09:02

Find Your Broker

DO NOT ACCEPT SOUTH AFRICA TRADERS, MINIMUM DEPOSIT 250$
IFSC AND CYSEC REGULATED - MINIMUM DEPOSIT $250
ACCEPT ONLY SOUTH AFRICA / ASIA TRADERS MINIMUM DEPOSIT 200$
CYSEC REGULATED, DO NOT ACCEPT USA / CANADA/ AUSTRALIA / FRANCE MINIMUM DEPOSIT 250€